Shares of BeiGene, a leading biopharmaceutical company based in Beijing, tumbled nearly 8.5% on Monday, mirroring the broader market selloff in Hong Kong amid growing uncertainty over the scale and timing of further economic stimulus measures from Chinese authorities.
The Hang Seng Index, Hong Kong's benchmark, fell 0.75% as investors were left disappointed after China's finance minister, Lan Foan, hinted at significantly increasing debt but failed to provide specific details on the size of the stimulus package during a press conference over the weekend.
BeiGene, along with other pharmaceutical giants like Innovent Biologics and CSPC Pharmaceutical, bore the brunt of the selloff, with their shares plunging around 5% at the close. Investor sentiment was further dampened by data released on Sunday showing a deceleration in consumer inflation and a prolonged decline in producer prices, fueling concerns over the health of the Chinese economy.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。